Stockscreener 앱 받기
24.88
8.50%
-2.31
전일 마감가:
$27.19
열려 있는:
$27.51
하루 거래량:
970.38K
Relative Volume:
2.77
시가총액:
$344.70M
수익:
-
순이익/손실:
$-8.89M
주가수익비율:
-35.54
EPS:
-0.7
순현금흐름:
$-6.48M
1주 성능:
-1.58%
1개월 성능:
+139.23%
6개월 성능:
+122.34%
1년 성능:
+97.93%
1일 변동 폭
$23.98
$27.51
1주일 범위
$22.81
$32.91
52주 변동 폭
$7.78
$32.91
그리니치 Stock (GLSI) Company Profile
명칭
Greenwich Lifesciences Inc
전화
203-434-3290
주소
3992 BLUEBONNET DR, BUILDING 14, STAFFORD
GLSI을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
GLSI
Greenwich Lifesciences Inc
|
24.88 | 376.70M | 0 | -8.89M | -6.48M | -0.70 |
|
VRTX
Vertex Pharmaceuticals Inc
|
441.36 | 111.36B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
733.04 | 77.98B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
800.01 | 50.33B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
359.27 | 47.46B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
338.19 | 37.43B | 4.98B | 69.59M | 525.67M | 0.5197 |
그리니치 Stock (GLSI) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-08-20 | 개시 | Noble Capital Markets | Outperform |
| 2021-09-01 | 개시 | H.C. Wainwright | Buy |
그리니치 주식(GLSI)의 최신 뉴스
Head to Head Contrast: Greenwich LifeSciences (NASDAQ:GLSI) & Vertex Pharmaceuticals (NASDAQ:VRTX) - Defense World
Insider Buying: Greenwich LifeSciences (NASDAQ:GLSI) CEO Acquires 1,800 Shares of Stock - MarketBeat
Greenwich LifeSciences CEO Patel buys $53,694 in GLSI stock By Investing.com - Investing.com Canada
The $69B Precision Pivot: Why Biomarker Platforms are Igniting a New Oncology Gold Rush - Baystreet.ca
Insider Buying: Greenwich LifeSciences (NASDAQ:GLSI) CEO Purchases 2,900 Shares of Stock - MarketBeat
Greenwich LifeSciences CEO Patel buys $79,866 in GLSI stock - Investing.com
Greenwich LifeSciences (GLSI) Price Target Increased by 13.10% to 48.45 - Nasdaq
Chart Watch: Will Greenwich LifeSciences Inc stock benefit from commodity pricesJuly 2025 Reactions & Entry Point Confirmation Signals - Bộ Nội Vụ
Technical Analysis: Is Greenwich LifeSciences Inc stock ready for breakoutTrade Exit Summary & Reliable Price Action Trade Plans - Bộ Nội Vụ
Why is GLSI stock rising today? - MSN
HER2-Positive Breast Cancer Pipeline 2025: FDA Updates, Therapy Innovations, and Clinical Trial Landscape Analysis by DelveInsight | Roche Pharma AG, Dizal Pharma, Greenwich LifeSciences, Ambrx - The Globe and Mail
Will Greenwich LifeSciences Inc. stock outperform growth indexesJuly 2025 Selloffs & Accurate Intraday Trading Signals - Улправда
Why Greenwich LifeSciences Inc. stock is a must watch in 2025Volume Weighted Average Price & Smart Beta Strategies That Actually Work - Улправда
How $594B in Precision Tech is Cracking the Metastatic Cancer Code - The Globe and Mail
Snehal Patel Buys Handful Of Shares In Greenwich LifeSciences - simplywall.st
Greenwich LifeSciences (NASDAQ:GLSI) CEO Snehal Patel Acquires 4,300 Shares - Defense World
Will Greenwich LifeSciences Inc. stock benefit from upcoming earnings reports2026 world cup usa national team group stage star players transition play group prediction preview - ulpravda.ru
A US$74m drop in the market cap of Greenwich LifeSciences, Inc. (NASDAQ:GLSI) is not what insiders like to see after purchasing shares recently - simplywall.st
Insider Buying: Greenwich LifeSciences (NASDAQ:GLSI) CEO Acquires 4,300 Shares of Stock - MarketBeat
Head-To-Head Analysis: Greenwich LifeSciences (NASDAQ:GLSI) vs. Avalon GloboCare (NASDAQ:ALBT) - Defense World
Snehal Patel Purchases 2,900 Shares of Greenwich LifeSciences (NASDAQ:GLSI) Stock - Defense World
Is Lehar Footwears Limited Poised for a PostEarnings RallyVolatility Adjusted Trading & Free Exceptional Risk Adjusted Gains - earlytimes.in
Insider Buying: Snehal Patel Acquires Additional Shares of Green - GuruFocus
Patel, Greenwich Lifesciences CEO, buys $63k in GLSI stock By Investing.com - Investing.com Nigeria
Greenwich LifeSciences (NASDAQ:GLSI) CEO Snehal Patel Buys 2,900 Shares - MarketBeat
Patel, Greenwich Lifesciences CEO, buys $63k in GLSI stock - Investing.com
FY2025 Earnings Estimate for GLSI Issued By HC Wainwright - MarketBeat
How (GLSI) Movements Inform Risk Allocation Models - Stock Traders Daily
New milestone in breast cancer prevention claimed by Greenwich - The Pharma Letter
Greenwich LifeSciences stock soars after extending insider lock-up By Investing.com - Investing.com India
Greenwich LifeSciences extends insider share lock-up to Sept 2026 By Investing.com - Investing.com Nigeria
Greenwich LifeSciences stock soars after extending insider lock-up - Investing.com
What's Going On With Greenwich LifeSciences Stock Monday? - One News Page
12 Health Care Stocks Moving In Monday's Intraday Session - Benzinga
Greenwich LifeSciences Takes Flight As FLAMINGO 01 Breast Cancer Trial Progresses - Nasdaq
Why Did GLSI Stock Surge 25% Today? - Stocktwits
Greenwich LifeSciences extends lock-up of shares to September 2026 - marketscreener.com
Greenwich LifeSciences Extends Lock-Up Of Shares To September 2026 - TradingView — Track All Markets
Greenwich LifeSciences Extends Share Lock-Up to September For Directors, Officers - marketscreener.com
Greenwich LifeSciences extends insider share lock-up to Sept 2026 - Investing.com
Greenwich LifeSciences, Inc. Announces Extension of Lock-Up Period for Shares to September 30, 2026 - Quiver Quantitative
Biotech locks insiders out of selling stock for six years to back cancer trial - Stock Titan
Greenwich LifeSciences (NASDAQ:GLSI) Raised to "Hold" at Wall Street Zen - MarketBeat
Greenwich LifeSciences (NASDAQ:GLSI) Raised to “Hold” at Wall Street Zen - Defense World
What's Going On With Greenwich LifeSciences Friday? - Sahm
Greenwich LifeSciences Provides Additional Updates on FLAMINGO-01 and Corporate Strategy - Sahm
Greenwich LifeSciences provides updates on Phase III breast cancer trial By Investing.com - Investing.com Nigeria
Greenwich Life Sciences Provides Updates On Breast Cancer Study; Outlines Corporate Strategy - Nasdaq
Greenwich LifeSciences says burn rate for 2025 $7M through first three quarters - TipRanks
Greenwich LifeSciences provides updates on Phase III breast cancer trial - Investing.com
그리니치 (GLSI) 재무 분석
매출
순이익
현금흐름
주당 순 이익
그리니치 주식 (GLSI) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Patel Snehal | CEO and CFO |
Jan 12 '26 |
Buy |
27.54 |
2,900 |
79,866 |
5,602,302 |
| Patel Snehal | CEO and CFO |
Dec 31 '25 |
Buy |
21.36 |
4,300 |
91,848 |
5,599,402 |
| Patel Snehal | CEO and CFO |
Dec 30 '25 |
Buy |
21.73 |
2,900 |
63,017 |
5,595,102 |
| Patel Snehal | CEO and CFO |
Dec 18 '25 |
Buy |
12.62 |
4,100 |
51,742 |
5,592,202 |
| Patel Snehal | CEO and CFO |
Nov 25 '25 |
Buy |
8.37 |
4,600 |
38,502 |
5,588,102 |
| Patel Snehal | CEO and CFO |
Nov 07 '25 |
Buy |
8.43 |
10,600 |
89,358 |
5,583,502 |
| Patel Snehal | CEO and CFO |
Oct 31 '25 |
Buy |
9.26 |
2,300 |
21,298 |
5,572,902 |
| Patel Snehal | CEO and CFO |
Apr 25 '25 |
Buy |
9.88 |
3,600 |
35,568 |
5,570,602 |
| Patel Snehal | CEO and CFO |
Apr 17 '25 |
Buy |
8.98 |
5,400 |
48,492 |
5,567,002 |
| Patel Snehal | CEO and CFO |
Apr 07 '25 |
Buy |
9.10 |
3,600 |
32,760 |
5,561,602 |
4.73%
0.92%
자본화:
|
볼륨(24시간):